Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 18/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 18/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 18/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2793984 | 0.97 | CHRM2 (0.37) | CHRM2CHRM1CHRM3 | |
| SCHEMBL3675637 | 0.95 | CHRM2 (0.41) | CHRM2CHRM1CHRM3 | |
| SCHEMBL3673741 | 0.94 | CHRM2 (0.38) | CHRM2CHRM1CHRM3 | |
| SCHEMBL3677129 | 0.94 | CHRM2 (0.38) | CHRM2CHRM1CHRM3 | |
| SCHEMBL3671867 | 0.80 | HTT (0.47) | CHRM2CHRM1CHRM3KDM4EALDH1A1 | |
| SCHEMBL4449850 | 0.79 | HTT (0.49) | CHRM2CHRM1CHRM3ALDH1A1HTT | |
| SCHEMBL3673737 | 0.77 | ALDH1A1 (0.46) | CHRM2CHRM1CHRM3ALDH1A1HTT | |
| SCHEMBL3677123 | 0.77 | ALDH1A1 (0.46) | CHRM2CHRM1CHRM3ALDH1A1HTT | |
| SCHEMBL3675633 | 0.75 | CHRM2 (0.46) | CHRM2CHRM1CHRM3 | |
| SCHEMBL4509630 | 0.74 | CHRM2 (0.55) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | claimed |
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004215-A1 | COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS | PDE4B, PDE4A, PDE3B | CHRM2 84/4885CHRM1 158/4885CHRM3 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.